NasdaqGS - Delayed Quote • USD
Sinovac Biotech Ltd. (SVA)
At close: April 4 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Apr 2024) | Next Qtr. (Jul 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.03 | -0.03 | -0.13 | -0.13 |
| Low Estimate | -0.03 | -0.04 | -0.15 | -0.13 |
| High Estimate | -0.02 | -0.03 | -0.11 | -0.13 |
| Year Ago EPS | -0.03 | -0.03 | -0.13 | -0.13 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Apr 2024) | Next Qtr. (Jul 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 4 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 4/30/2023 | 7/31/2023 | 10/31/2023 | 1/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.02 | -0.02 | -0.02 | -0.03 |
| EPS Actual | -0.03 | -0.03 | -0.04 | -0.03 |
| Difference | -0.01 | -0.01 | -0.02 | 0 |
| Surprise % | -50.00% | -50.00% | -100.00% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Apr 2024) | Next Qtr. (Jul 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.03 | -0.03 | -0.13 | -0.13 |
| 7 Days Ago | -0.03 | -0.03 | -0.13 | -0.13 |
| 30 Days Ago | -0.03 | -0.03 | -0.14 | -0.13 |
| 60 Days Ago | -0.03 | -0.03 | -0.08 | -0.12 |
| 90 Days Ago | -0.02 | -0.02 | -0.06 | -0.08 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Apr 2024) | Next Qtr. (Jul 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SVA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 0.00% | -- | -- | 5.40% |
| Next Qtr. | 0.00% | -- | -- | 10.90% |
| Current Year | 0.00% | -- | -- | 4.50% |
| Next Year | 0.00% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | Morgan Stanley: Overweight | 3/20/2014 |
| Maintains | Aegis Capital: Buy | 11/13/2013 |
| Upgrade | Aegis Capital: Hold to Buy | 8/15/2013 |
| Upgrade | Morgan Stanley: Underperform to Equal-Weight | 5/15/2013 |
| Maintains | Aegis Capital: Hold | 3/14/2013 |
| Initiated | Aegis Capital: Hold | 12/12/2012 |
Related Tickers
688136.SS Kexing Biopharm Co., Ltd.
15.28
+0.73%
HSTC HST Global, Inc.
1.1100
+18.09%
YECO EV Biologics, Inc.
0.6221
+3.32%
LIPO Lipella Pharmaceuticals Inc.
0.7110
+0.98%
ACHL Achilles Therapeutics plc
0.7600
-2.69%
FBRX Forte Biosciences, Inc.
0.7163
-0.07%
SVA.TO Sernova Corp.
0.4400
+3.53%
XCUR Exicure, Inc.
0.5001
-1.56%
SXTP 60 Degrees Pharmaceuticals, Inc.
0.2376
-0.50%
CMMB Chemomab Therapeutics Ltd.
0.6399
-2.90%